{
    "clinical_study": {
        "@rank": "119251", 
        "acronym": "RESCUE-L", 
        "arm_group": {
            "arm_group_label": "Azithromycin IV", 
            "description": "Subjects who are treated with Azithromycin IV for Legionnaires' disease"
        }, 
        "brief_summary": {
            "textblock": "To collect retrospectively the efficacy and safety information of azithromycin IV on\n      patients with Legionnaires' disease related to their appropriate use in daily practice."
        }, 
        "brief_title": "Special Investigation Of Azithromycin IV For Legionnaires' Disease (Regulatory Post Marketing Commitment Plan)", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Legionnaires' Disease", 
            "Legionella Pneumophila Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Legionnaires' Disease", 
                "Legionellosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients who are prescribed Azithromycin (Zithromac) IV for Legionnaires'\n             disease.\n\n        Exclusion Criteria:\n\n          -  Patients who have been prescribed Zithromac or Zithromac SR."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "The patients whom an investigator involving A0661208 prescribes the Zithromac IV."
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01784770", 
            "org_study_id": "A0661208"
        }, 
        "intervention": {
            "arm_group_label": "Azithromycin IV", 
            "description": "The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.\nThe recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy.", 
            "intervention_name": "Azithromycin IV", 
            "intervention_type": "Drug", 
            "other_name": "Zithromac IV"
        }, 
        "intervention_browse": {
            "mesh_term": "Azithromycin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Legionnaires' disease", 
            "Legionella pneumophila", 
            "Zithromax", 
            "Zithromac", 
            "Japanese", 
            "Regulatory Post Marketing Commitment Plan"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0661208&StudyName=Special%20Investigation%20Of%20Azithromycin%20IV%20For%20Legionnaires%27%20Disease%20%28Regulatory%20Post%20Marketing%20Commitment%20Plan%29"
        }, 
        "number_of_groups": "1", 
        "official_title": "Research Of Effectiveness And Safety On Patients With Legionella Pneumophila Infections, Continuous Treatment With Azithromycin IV And Tab Utilized As The First Administrative Evaluation for Legionnaires' Disease (RESCUE-L)", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The clinical response was assigned by the investigator. A clinical response of cure was defined as: Test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection. Test-of-cure performed 10-28 days after last dose of study drug.", 
            "measure": "Number of Participants with Clinical Response of Cure at the Test-of-Cure (TOC) Visit", 
            "safety_issue": "No", 
            "time_frame": "29 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01784770"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}